Improving cognitive functioning in major depressive disorder with psychedelics: A dimensional approach
Neurobiology of Learning and Memory May 25, 2021 Igor Magaraggia, Zilla Kuiperes, Rudy Schreiber 49 citations
Major depressive disorder's high heterogeneity makes broad treatments difficult. Focusing on single, biologically understood core symptoms may be more viable. The Research Domain Criteria framework offers a trans-diagnostic dimensional approach. Psychedelics show potential antidepressant activity, possibly explained through multi-level analysis of cognitive systems. Cognitive deficits like negative emotional processing and negativity bias lead to depressive rumination. Psychedelics increase long-term cognitive flexibility, normalizing negativity bias and reducing rumination.